Skip to main content

IL-23

Dr. John Cush
@RheumNow
Is It Still Inflammation? A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/fLGgnBCXS8
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, obesity in PsA: 81.8% prevalence of overweight or obesity in a US cohort, lower ACR50 at higher BMI on bimekizumab, and higher ACR50 with ixekizumab plus tirzepatide at 52 weeks. @rheumnow #ACR26 Abstract#2015 Abstract#1305 Abstract#2942
Janet Pope
@Janetbirdope
#H2H #RCTs in #PsA, #PsO Of #IL17i vs #IL23i /IL12/23i For #PsO IL23i>IL17i #guselkumab >secukinumab #Secukinumab>#ustekinumab for #HAQ DI in PsA #PsA #bimekizumab>#risankizumab depends on what you want as outcome #psoriasis v #psoriatic #arthritis #ACR26 @RheumNow #2804 https://t.co/kOQiC5O68Y

ACR 2026 Day 3 Report

Jack Cush, MD

Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

Antoni Chan MD (Prof)
@synovialjoints
Late breaking, ICONIC PsA 1: icotrokinra, a once daily oral peptide targeting the IL23 receptor, in biologic naive PsA. Week 16 ACR20 58% vs 41% with placebo; ACR50 29% vs 16%; clear or almost clear skin 57% vs 14%. Key finding: the primary endpoint was met, with ACR20 69% and
Brian Jaros, MD
@Dr_Brian_MD
Which patient with ICI joint disease will have persistent disease? Risk factors include: - tenosynovitis on US/MRI - elevated CRP - baseline GC use - age <65 - peripheral inflam arthritis pattern @RheumNow #ACR26 Abst2806
Audrey Gibson
@Gibson_RheumPAC
Weber et al. (TOGETHER cardiometabolic analysis): PsA and psoriasis are cardiovascular stories too. In TOGETHER analyses, combining ixekizumab and tirzepatide improved blood pressure and waist-to-height metrics. @rheumnow #ACR2026 Abstract#2299
Jiha Lee
@JihaRheum
Do women respond less to PsA advanced therapies? Meta-analysis of 11 studies: males higher ACR20, ACR50 and MDA (OR 1.42, 1.74, 1.94). Differences were seen with TNFi, IL-17i, IL-23i and IL-12/23i, but not TYK2i. Yet placebo response was equal by sex. A#2309 @RheumNow #ACR26
Audrey Gibson
@Gibson_RheumPAC
An ORAL IL-23 receptor inhibitor for PsA? Phase 3 data evaluate icotrokinra, an oral peptide targeting IL-23R, through Week 24 in biologic-naïve PsA. Could oral targeted therapy expand our options beyond injectable biologics? Kishimoto et al. | #LB12 @RheumNow #ACR26
Audrey Gibson
@Gibson_RheumPAC
Kishimoto et al: ICONIC-PsA 1 tested oral IL-23R peptide icotrokinra in biologic-naive PsA. Week 16 ACR20: 58% with 200 mg vs 41% placebo (p=0.002). Oral targeted therapy could expand PsA choices. @rheumnow #ACR2026 Abstract#LB12
Antoni Chan MD (Prof)
@synovialjoints
DESIR analysis: the 2025 ASAS SPARTAN criteria classified 44% of 663 patients with early axSpA vs 63% with ASAS 2009. Key finding: sensitivity was lower with the new criteria, mainly in the clinical arm (30.1% to 0.8%), affecting mostly HLA B27 positive patients. @rheumnow #ACR26
Antoni Chan MD (Prof)
@synovialjoints
IL17Ai vs IL23i in PsA, US registry, 385 vs 233 patients: class persistence at 12 months 56.2% vs 57.4% (HR 1.06), drug persistence 48.9% vs 54.1% (HR 1.19). Key finding: persistence did not differ significantly between the two classes. @rheumnow #ACR26 Abstract#2288
Antoni Chan MD (Prof)
@synovialjoints
Dual targeted therapy in 76 patients with refractory SpA or PsA (Spain), most often TNFi plus IL12/23i. Key finding: 55.6% reached remission during follow up, and adverse events accounted for a third of discontinuations. @rheumnow #ACR26 Abstract#1322
×